This study aimed to characterize premature mortality among people diagnosed with HIV infection from 2000 to 2009 in Florida, by sex and race/ethnicity, to estimate differences in premature mortality that could be prevented by linkage to HIV care and treatment.
Methods.
Florida surveillance data for HIV diagnoses (excluding concurrent AIDS diagnoses) were linked with vital records data to ascertain deaths through 2011. Years of potential life lost (YPLL) were obtained from the expected number of remaining years of life at a given age from the U.S. sex-specific period life tables.
Results.
Among 41,565 people diagnosed with HIV infection during the study period, 5,249 died, and 2,563 (48.8%) deaths were due to HIV/AIDS. Age-standardized YPLL (aYPLL) due to HIV/AIDS per 1,000 person-years was significantly higher for females than males (372.6, 95% confidence interval [CI] 349.8, 396.2 vs. 295.2, 95% CI 278.4, 312.5); for non-Hispanic black (NHB) females than non-Hispanic white (NHW) and Hispanic females (388.2, 95% CI 360.7, 416.9; 294.3, 95% CI 239.8, 354.9; and 295.0, 95% CI 242.9, 352.5, respectively); and for NHB males compared with NHW and Hispanic males (378.7, 95% CI 353.7, 404.7; 210.6, 95% CI 174.3, 250.8; and 240.9, 95% CI 204.8, 280.2, respectively). In multilevel modeling controlling for individual factors, NHB race was associated with YPLL due to HIV/AIDS for women (p=0.04) and men (p<0.001).
Conclusion.
Among people diagnosed with HIV infection, females and NHB people had a disproportionately high premature mortality from HIV/AIDS, suggesting the need for enhanced efforts to improve linkage to and retention in care and medication adherence for these groups.
References
1.
PrejeanJSongRHernandezAZiebellRGreenTWalkerF, Estimated HIV incidence in the United States, 2006–2009. PLoS One2011;6:e17502.
2.
National Center for Health Statistics (US). Health, United States, 2013: With special feature on prescription drugs. Hyattsville (MD): NCHS; 2014. Also available from: URL: http://www.cdc.gov/nchs/data/hus/hus13.pdf [cited 2013 Nov 18].
3.
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet2008;372:293–9.
4.
SamjiHCesconAHoggRSModurSPAlthoffKNBuchaczK, Closing the gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One2013;8;e81355.
5.
KrentzHBKliewerGGillMJ, Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med2005;6:99–106.
6.
BonnetFBurtyCLewdenCCostagliolaDMayTBouteloupV, Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 Survey. Clin Infect Dis2009;48:633–9.
7.
CohenMHFrenchALBenningLKovacsAAnastosKYoungM, Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med2002;113:91–8.
8.
CrumNFRiffenburghRHWegnerSAganBKTaskerSASpoonerKM, Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr2006;41:194–200.
9.
PachecoAGTuboiSHMaySBMoreiraLFRamadasLNunesEP, Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr2009;51:624–30.
10.
WadaNJacobsonLPCohenMFrenchAPhairJMuñozA.Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. Am J Epidemiol2013;177:116–25.
11.
HallHIFrazierELRhodesPHoltgraveDRFurlow-ParmleyCTangT, Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med2013;173:1337–44.
12.
GardnerJWSanbornJS, Years of potential life lost (YPLL)—what does it measure?Epidemiology1990;1:322–9.
13.
SchneiderEWhitmoreSGlynnMKDominguezKMitschAMcKennaMT, Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recomm Rep2008;57(10):1–8.
14.
FlemingPLWardJWJanssenRSDe CockKMValdiserriROGayleHD, Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Recomm Rep1999;48(RR13):1–28.
15.
Centers for Disease Control and Prevention, Health Resources and Services Administration (US), National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, the National Minority AIDS Council and the Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014. Atlanta: CDC; 2014. Also available from: URL: http://stacks.cdc.gov/view/cdc/26062 [cited 2015 Feb 10].
16.
World Health Organization. International classification of diseases, tenth revision. 1994 [cited 2014 Feb 3]. Available from: URL: http://www.who.int/classifications/icd/en.
17.
KochanekKDAriasEAndersonRN, How did cause of death contribute to racial differences in life expectancy in the United States in 2010. NCHS Data Brief2013;125:1–8.
TrepkaMJNiyonsengaTMaddoxLLiebSLutfiKPavlova-McCallaE.Community poverty and trends in racial/ethnic survival disparities among people diagnosed with AIDS in Florida, 1993–2004. Am J Public Health2013;103:717–26.
21.
AriasE.United States life tables, 2009. Natl Vital Stat Rep2014 Jan 16;62:1–63.
22.
AriasE.United States life tables, 2008. Natl Vital Stat Rep2012 Sep 24;61:1–64.
23.
AriasE.United States life tables, 2007. Natl Vital Stat Rep2011 Sep 28;59:1–61.
24.
AriasE.United States life tables, 2006. Natl Vital Stat Rep2010 Jun 28;58:1–40.
25.
AriasERostronBLTejada-VeraB.United States life tables, 2005. Natl Vital Stat Rep2010 Mar 3;58:1–132.
26.
BergenHHawtonKWatersKNessJCooperJSteegS, Premature death after self-harm: A multicentre cohort study. Lancet2012;380:1568–74.
27.
DegenhardtLLarneySRandallDBurnsLHallW.Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction2014;109:90–9.
28.
HarrisonKMSongRZhangX.Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr2010;53:124–30.
29.
PhamTMFujinoYIdeRTokuiNKuboTMizoueT, Years of life lost due to cancer in a cohort study in Japan. Eur J Public Health2009;19:189–92.
30.
SeifarthJEMcGowanCLMilneKJ, Sex and life expectancy. Gend Med2012;9:390–401.
31.
KleinRJSchoenbornCA, Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes2001;(20):1–10.
32.
FayMPFeuerEJ, Confidence intervals for directly standardized rates: A method based on the gamma distribution. Stat Med1997;16:791–801.
KiernanKTaoJGibbsP.Tips and strategies for mixed modeling with SAS/STAT$ procedures. Paper 332–2012. Cary (NC): SAS Institute, Inc.; 2012.
36.
SAS Institute, Inc.SAS$: Version 9.3. Cary (NC): SAS Institute, Inc.; 2010.
37.
BastardMSoulinphumyKPhimmasonePSaadaniAHCiaffiLCommunierA, Women experience a better long-term immune recovery and a better survival on HAART in Lao People/s Democratic Republic. BMC Infect Dis2013;13:27.
38.
JarrinIGeskusRBhaskaranKPrinsMPerez-HoyosSMugaR, Gender differences in HIV progression to AIDS and death in industrialized countries: Slower disease progression following HIV seroconversion in women. Am J Epidemiol2008;168:532–40.
39.
NicastriELeoneSAngelettiCPalmisanoLSarmatiLChiesiA, Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review. J Antimicrob Chemother2007;60:724–32.
40.
GeboKAFleishmanJAConviserRReillyEDKorthuisPTMooreRD, Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr2005;38:96–103.
41.
GiordanoTPWhiteACJrSajjaPGravissEAArduinoRCAdu-OppongA, Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr2003;32:399–405.
42.
McNaghtenADHansonDLDworkinMSJonesJL; Adult/Adolescent Spectrum of HIV Disease Group. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr2003;32:499–505.
43.
HorstmannEBrownJIslamFBuckJAginsBD, Retaining HIV-infected patients in care: Where are we?Where do we go from here? Clin Infect Dis2010;50:752–61.
44.
WohlARGalvanFHMyersHFGarlandWGeorgeSWittM, Do social support, stress, disclosure and stigma influence retention in HIV care for Latino and African American men who have sex with men and women?AIDS Behav2011;15:1098–110.
45.
RubinMSColenCGLinkBG, Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. Am J Public Health2010;100:1053–9.
46.
AnQHernandezAPrejeanJGermanEJThompsonHHallHI, Geographic differences in HIV infection among Hispanics or Latinos—46 states and Puerto Rico, 2010. MMWR Morb Mortal Wkly Rep2012;61(40):805–10.
47.
MacartneySBishawAFontenotK.Poverty rates for selected detailed race and Hispanic groups by state and place: 2007–2011. American Community Survey Briefs February 2013. Department of Commerce, Census Bureau (US): Washington; 2013.
48.
PhillipsANNeatonJLundgrenJD, The role of HIV in serious diseases other than AIDS. AIDS2008;22:2409–18.
49.
Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2012. HIV Surveill Rep2012;24:1–83.
